News Column

Study Results from L.B. Cohen et al Provide New Insights into Inflammatory Bowel Diseases (Biologic therapies in inflammatory bowel disease)

July 2, 2014



By a News Reporter-Staff News Editor at Biotech Week -- Current study results on Digestive System Diseases and Conditions have been published. According to news reporting originating in Toronto, Canada, by NewsRx journalists, research stated, "Inflammatory bowel disease, including its 2 entities ulcerative colitis and Crohn's disease, is a chronic medical condition characterized by the destructive inflammation of the intestinal tract. Biologics represent a class of therapeutics with immune intervention potential."

The news reporters obtained a quote from the research, "These agents block the proinflammatory cascade that triggers the activation and proliferation of T lymphocytes at the level of the intestine, therefore reestablishing the balance between the pro- and anti-inflammatory messages. All 7 biologics showing clinical benefits in inflammatory bowel disease are monoclonal antibodies. The following systematic review discusses the pharmacokinetics and efficacy of the tumor necrosis factor blockers infliximab, adalimumab, certolizumab pegol, and golimumab."

According to the news reporters, the research concluded: "In addition, we describe the alpha(4) integrin inhibitors natalizumab and vedolizumab, which are directed against cell adhesion molecules, as well as the interleukin 12/23 blocker ustekinumab."

For more information on this research see: Biologic therapies in inflammatory bowel disease. Translational Research, 2014;163(6):533-556. Translational Research can be contacted at: Elsevier Science Inc, 360 Park Ave South, New York, NY 10010-1710, USA. (The Endocrine Society - www.endo-society.org/; Translational Research - www.endojournals.org/site/trem/)

Our news correspondents report that additional information may be obtained by contacting L.B. Cohen, In Vitro Drug Safety & Biotechnol, Toronto, ON M5G 1L7, Canada. Additional authors for this research include R.M. Nanau, F. Delzor and M.G. Neuman (see also Digestive System Diseases and Conditions).

Keywords for this news article include: Biotechnology, Canada, Toronto, Ontario, Biologicals, Gastroenteritis, North and Central America, Gastrointestinal Diseases, Inflammatory Bowel Diseases, Digestive System Diseases and Conditions

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC


For more stories covering the world of technology, please see HispanicBusiness' Tech Channel



Source: Biotech Week


Story Tools






HispanicBusiness.com Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters